These tests identified ER-related genes and proliferation markers as the two most powerful molecular processes to predict an initial clinical outcome (i.e., the first 5-years) but are not able to predict late recurrences, a relatively common issue in ER-positive breast cancer [89]. The gene discussed is ESR1; the disease is breast carcinoma.